Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
NCT06784336Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox, resistant potato starch in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Started Oct 2025; status: recruiting.
02
Drugs
deferasiroxresistant potato starch
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06784336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784336.